{"id":"NCT01462357","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females","officialTitle":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-21","primaryCompletion":"2015-10-27","completion":"2015-10-27","firstPosted":"2011-10-31","resultsPosted":"2016-03-28","lastUpdate":"2019-11-15"},"enrollment":1079,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Papillomavirus"],"interventions":[{"type":"BIOLOGICAL","name":"Cervarix","otherNames":[]},{"type":"BIOLOGICAL","name":"Gardasil","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cervarix 2 dose Group","type":"EXPERIMENTAL"},{"label":"Gardasil 2 dose Group","type":"EXPERIMENTAL"},{"label":"Gardasil 3 dose Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered according to a 2-dose schedule at 0, 6 months or the standard 3-dose schedule of 0, 2, 6 months in 9-14 years old healthy females.","primaryOutcome":{"measure":"Number of Seroconverted Subjects for Anti-HPV-16/18 Antibodies as Assessed by Enzyme-Linked Immunosorbent Assay (ELISA) at Month 7 Based on the ATP Cohort for Immunogenicity","timeFrame":"At Month 7 (i.e. one month after the last dose of study vaccine)","effectByArm":[{"arm":"Cervarix 2 Dose Group","deltaMin":330,"sd":null},{"arm":"Gardasil 2 Dose Group","deltaMin":327,"sd":null},{"arm":"Gardasil 3 Dose Group","deltaMin":322,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"9 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":21,"countries":["France","Hong Kong","Singapore","Sweden"]},"refs":{"pmids":["26062002","29174109"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":359},"commonTop":["Pain","Fatigue","Erythema","Myalgia","Headache"]}}